Biotech / Finance

Akari Therapeutics Announces R&D Day on April 24, 2017

From Biotech
March 17, 2017 - 7:00am
NEW YORK and LONDON, March 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research and Development Day on April 24, 2017 in New York. The event will be hosted by members of Akari's executive leadership team and will feature presentations from investigators and independent scientific advisors. The meeting will cover three main areas: Interim results from the ongoing phase 2 trial in paroxysmal nocturnal hemoglobinuria (PNH) will be presented by Dr Anita Hill, the lead investigator in the study.  Dr Hill is a Consultant Haematologist and Honorary Clinical Associate Professor at Leeds Teaching Hospital, which is one of the world's largest treatment centers for PNH patients.   Results from the pre-clinical development program targeting new disease opportunities for our lead compound Coversin, focusing on its unique dual leukotriene B4 (LTB4)/C5 activity will be presented by Dr Robert Snelgrove, National Heart and Lung Institute, Imperial College London whose particular expertise lies in LTB4 and lung inflammation.   New data on the pre-clinical pipeline, including the once-weekly subcutaneous formulation of Coversin, will be presented by Professor Arne Skerra, Professor of Biological Chemistry at the University of Munich and Chairman of XL-protein GmbH. The presentation will be webcast simultaneously. Details of how to access the presentation and simultaneous webcast will be posted on the calendar section of the Company's website (www.akaritx.com) a week ...Full story available on Benzinga.com


Continue reading this article »